Macrolide Resistance in Streptococcus pneumoniae by Max R. Schroeder & David S. Stephens
MINI REVIEW
published: 21 September 2016
doi: 10.3389/fcimb.2016.00098
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 1 September 2016 | Volume 6 | Article 98
Edited by:
Guangchun Bai,
Albany Medical College, USA
Reviewed by:
Lesley McGee,
Centers for Disease Control and
Prevention, USA
Werner Albrich,
Kantonsspital St. Gallen, Switzerland
Lucia Martins Teixeira,





Received: 12 May 2016
Accepted: 26 August 2016
Published: 21 September 2016
Citation:
Schroeder MR and Stephens DS
(2016) Macrolide Resistance in
Streptococcus pneumoniae.




Max R. Schroeder 1 and David S. Stephens 1, 2, 3*
1Departments of Medicine, Emory University, Atlanta, GA, USA, 2Departments of Microbiology and Immunology, Emory
University, Atlanta, GA, USA, 3Departments of Epidemiology, Emory University, Atlanta, GA, USA
Streptococcus pneumoniae is a common commensal and an opportunistic pathogen.
Suspected pneumococcal upper respiratory infections and pneumonia are often treated
with macrolide antibiotics. Macrolides are bacteriostatic antibiotics and inhibit protein
synthesis by binding to the 50S ribosomal subunit. The widespread use of macrolides is
associated with increased macrolide resistance in S. pneumoniae, and the treatment
of pneumococcal infections with macrolides may be associated with clinical failures.
In S. pneumoniae, macrolide resistance is due to ribosomal dimethylation by an
enzyme encoded by erm(B), efflux by a two-component efflux pump encoded by
mef (E)/mel(msr(D)) and, less commonly, mutations of the ribosomal target site of
macrolides. A wide array of genetic elements have emerged that facilitate macrolide
resistance in S. pneumoniae; for example erm(B) is found on Tn917, while themef (E)/mel
operon is carried on the 5.4- or 5.5-kb Mega element. The macrolide resistance
determinants, erm(B) and mef (E)/mel, are also found on large composite Tn916-like
elements most notably Tn6002, Tn2009, and Tn2010. Introductions of 7-valent and
13-valent pneumococcal conjugate vaccines (PCV-7 and PCV-13) have decreased
the incidence of macrolide-resistant invasive pneumococcal disease, but serotype
replacement and emergence of macrolide resistance remain an important concern.
Keywords: Streptococcus pneumoniae, antibiotic resistance, macrolide resistance, erm(B),mef(A/E)/mel(msr(D)),
Mega, pneumococci
INTRODUCTION
Streptococcus pneumoniae, the pneumococcus, is a commensal of the human nasopharynx and
an opportunistic pathogen that is a leading worldwide cause of death for children under the
age of 5 years (Walker et al., 2013). In addition to localized infections such as otitis media and
pneumonia, the pneumococcus may cause severe invasive disease (IPD) including bacteremia and
meningitis. Development of penicillin resistance in the pneumococcus in the 1980s–1990s shifted
antibiotic treatment of suspected pneumococcal upper respiratory infections and pneumonia to
macrolides. Widespread macrolide use, however, is associated with increased macrolide resistance
in S. pneumoniae (Bergman et al., 2006; Malhotra-Kumar et al., 2007). Clinical failures of
macrolide treatment of pneumococcal infections have been reported for lower respiratory tract
infections (Klugman, 2002) and bacteremia (Lonks et al., 2002; Schentag et al., 2007). Widespread
macrolide use is a strong selective pressure contributing to the expansion of macrolide-resistant
S. pneumoniae (Bergman et al., 2006; Keenan et al., 2015). Globally, macrolide resistance among
S. pneumoniae is geographically variable but ranges from <10% to >90% of isolates (Farrell et al.,
2008; Pan et al., 2015; Xiao et al., 2015).
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MACROLIDE ANTIBIOTICS
Macrolides are defined by a complex macrocyclic structure with
a 14-, 15-, or 16-membered lactone ring substituted with neutral
or amino sugar groups. Macrolides inhibit bacterial protein
synthesis by binding to the large 50S ribosomal subunit and
disrupting protein elongation by causing the dissociation of the
peptidyl-tRNA.
Erythromycin, discovered in 1952, is a 14-membered
macrolide produced by Saccharopolyspora erythraeus (formerly
Streptomyces erythraeus; McGuire et al., 1952). After the
discovery of erythromycin and other naturally-produced
macrolides, research focused on the creation of synthetic and
semisynthetic macrolides (Kirst, 2010; Seiple et al., 2016).
Azithromycin and clarithromycin are semisynthetic macrolides
approved for use in the United States, and azithromycin is one
of the most prescribed antibiotics in the US (Hicks et al., 2015).
Additional macrolides such as roxithromycin and josamycin
are approved in other countries worldwide. Macrolides bind
reversibly to the 23S rRNA at a site near the peptidyl transferase
center of the 50S ribosomal subunit (Kannan andMankin, 2011).
Macrolide binding occurs in pre-structured ribosomal assemblies
(Pokkunuri and Champney, 2007). The smaller macrolides (14-
and 15-membered) partially block the nascent peptide channel
to inhibit the elongating peptide chain while larger macrolides
(16-membered) fully block the nascent peptide channel and
cause ribosomal disassociation that reversibly inhibits protein
synthesis (Weisblum, 1995b). Though distinct in chemical
structure, the lincosamide and streptogramin class antibiotics
have overlapping binding sites with macrolides and have similar




Erythromycin ribosomal methylase (erm) family genes encode
adenine-specific N-methyltransferases that methylate the 23S
rRNA to prevent antibiotic binding (Weisblum, 1995a). The
ribosomal methylase found in S. pneumoniae is primarily
encoded by erm(B) whose gene product dimethylates the target
site of the 23S rRNA (A2058 in Escherichia coli; Skinner et al.,
1983; Johnston et al., 1998). The erm(B) gene is themost common
macrolide resistance determinant in S. pneumoniae (Table 1).
Erm(A) subclasses erm(A) (Syrogiannopoulos et al., 2001) and
erm(TR) (Camilli et al., 2008) are rarely found in S. pneumoniae.
Ribosomal methylation by Erm(B) confers resistance to
macrolides, lincosamides, and streptogramin B, which is
characterized as the MLSB phenotype (Weisblum, 1995a). In
addition to the expanded spectrum of resistance, erm(B) provides
high-level resistance to macrolides (erythromycin MICs usually
≥256µg/ml).
The induction of erm(B) allows high-level translation of
Erm(B) in the presence of inducers such as erythromycin
(Chancey et al., 2011). In the pneumococcus, erm(B) expression
may be inducible or constitutively expressed to high levels. As
expression of erm genes is repressed in the absence of inducing
drugs through a mechanism of translational attenuation; erm(B)
expression has been proposed to have a bacterial fitness cost
(Min et al., 2008; Chancey et al., 2012; Gupta et al., 2013). A
recent study found that a Staphylococcus aureus strain expressing
erm(C) was outcompeted by S. aureus expressing catalytically-
inactive erm(C) (Gupta et al., 2013), supporting the need for
tight regulation of expression. Interestingly, deletion of the
leader sequence of erm(B) in S. pneumoniae was found to
confer resistance to telithromycin, the first-generation ketolide,
a semi-synthetic macrolide antibiotic, by allowing constitutive
expression (Wolter et al., 2008).
Macrolide Efflux
Macrolide eﬄux in S. pneumoniae has been the most common
cause of macrolide resistance in North America, the United
Kingdom, and others (Table 1). Pneumococcal macrolide eﬄux
is encoded by the mef (E)/mel operon and occurs through
an as yet incompletely understood mechanism of macrolide
binding and membrane targeting for eﬄux (Chancey et al.,
2012). Macrolide resistance in S. pneumoniae requires both
mef (E) and mel. These genes are carried on the macrolide eﬄux
genetic assembly (Mega) element and are expressed from a
single promoter inducible by 14- and 15-membered macrolides
(e.g., erythromycin, clarithromycin, and azithromycin; Gay and
Stephens, 2001; Ambrose et al., 2005; Chancey et al., 2015b).
Expression of mef (E) and mel is tightly controlled through
transcriptional attenuation (Chancey et al., 2015b).
The first gene, mef (E) shares 90% sequence identity with
mef (A) from Streptococcus pyogenes (Tait-Kamradt et al., 1997;
Roberts et al., 1999). While mef (E) is most common, mef (A) is
more common in Germany, Denmark, and Australia (Table 1).
Another homolog, mef (I), also shares 91% identity with mef (A),
has been found in S. pneumoniae (Cochetti et al., 2005;
Wierzbowski et al., 2005b) but is rarely found (Table 1). Most
studies do not distinguish between mef (E) and mef (A) and thus
report only mef (E) or mef (A) rather than mef (A/E), which is a
more accurate description of the data. In S. pneumoniae, mef (E)
encodes a 405 amino acid protein that belongs to the major
facilitator superfamily, which utilizes proton motive force-driven
eﬄux to expel molecules from cells (Tait-Kamradt et al., 1997).
The second gene, mel (also known as msr(D)) is a homolog
of the S. aureus gene mrs(A) (Roberts et al., 1999), which
encodes an ATP-binding cassette (ABC) transporter protein
but lacks typical hydrophobic, membrane-binding domains,
and is predicted to interact with chromosomally encoded
transmembrane complexes (Ambrose et al., 2005). Mef(E) and
Mel have been shown to synergistically provide macrolide
resistance and operate as a two-component eﬄux pump in S.
pneumoniae (Ambrose et al., 2005; Zhang et al., 2016). A recent
E. coli study suggests a physical interaction between Mef(E)
and Mel and that Mel may bind macrolides and localize to
the membrane (Nunez-Samudio and Chesneau, 2013). In S.
pyogenes the presence ofmsr(D) alone was required formacrolide
resistance (Zhang et al., 2016) and recent evidence suggests
antibiotic resistance by ATP-binding cassette proteins may occur
through ribosomal protection by displacing ribosome-bound
macrolide molecules (Sharkey et al., 2016). Thus, the working
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TABLE 1 | Distribution of macrolide resistance genotypes by country.
Continent
Country
Macrolide resistance genotype distribution % Years References
erm(B) mef(A/E) mef(E) mef(A) erm(B) + mef(E) Negativea
AFRICA
Morocco 90.2 6.5 0 3.3 0 2007–2014 Diawara et al., 2016
South Africa 36.5 16.3 46.4 0.4 2003–2004 Farrell et al., 2008
ASIA
China 63.4 0.6 36.0 0 2006–2008 Ma et al., 2013
69.6 0 30.4 2010 Zhou et al., 2011
62.9 37.1 2012–2013 Geng et al., 2014
Hong Kong 45.9 27.7 26.4 0 2008–2009 Kim et al., 2012
Iran 44 16 40 2011–2013 Azadegan et al., 2015
Japan 56.3 28.8 10.9 4.0 2011 Kawaguchiya et al., 2014
59.5 25.2 12.6 2.7 2011–2012 Okade et al., 2014
53.2 21.8 17.9 7.1 2012 Chiba et al., 2014
Jordan 26.4 24.5 13.2 35.8 2012–2013 Swedan et al., 2016
Lebanon 65.3 0 19.5 14.6 2005–2009 Daoud et al., 2011
36.4 18.1 31.8 13.6 2008–2010 Taha et al., 2012
Malaysia 35.2 42.6 9.3 13.0 2008–2009 Kim et al., 2012
Saudi Arabia 37.5 62.5 0 0 2003–2004 Farrell et al., 2008
Sri Lanka 73.3 13.3 13.3 0 2008–2009 Kim et al., 2012
South Korea 43.3 13.0 43.3 0.4 2008–2009 Kim et al., 2012
Taiwan 55.1 22.5 21.4 1.0 2008–2009 Kim et al., 2012
70.0 5.0 25.0 2010 Safari et al., 2014
Thailand 47.9 37.2 11.7 3.2 2008–2009 Kim et al., 2012
Vietnam 56.9 2.1 41.0 0 2008–2009 Kim et al., 2012
AUSTRALIA
Australia 32.4 3.9 20.6 35.3 (6.9)b 0.9 2005 Xu et al., 2010
EUROPE
Austria 45.5 54.5 0 0 2003–2004 Farrell et al., 2008
Belgium 90.2 1.6 3.3 4.9 2007–2009 Lismond et al., 2012
Bulgaria 63.2 21.0 15.8 2006–2010 Setchanova et al., 2012
Denmark 30.4 15.9 49.3
(1.4)c
0 2 2007 Nielsen et al., 2010
France 90.0 2.4 1.2 6.5 2003–2004 Farrell et al., 2008
Finland 30.5 40.4 15.7 0.9 12.6 2002–2006 Siira et al., 2009
Germany 27.0 11.2 57.7 4.1 0 2005–2006 Bley et al., 2011
66.8 8.3 20.7 3.6 2012–2013 Imöhl et al., 2015
Greece 22.0 45.8 0 32.2 2009 Grivea et al., 2012
Hungary 82.4 11.8 5.9 0 2003–2004 Farrell et al., 2008
Ireland 38.9 61.1 0 0 2003–2004 Farrell et al., 2008
Italy 55.8 38.5 1.0 4.8 2003–2004 Farrell et al., 2008
Poland 80.8 7.7 3.8 7.7 2003–2004 Farrell et al., 2008
Russia 54.1 12.7 30.6 2.6 2009–2013 Mayanskiy et al., 2014
Slovak Republic 64.7 5.9 17.6 11.8 2003–2004 Farrell et al., 2008
Spain 74.3 7.7 17.9 2000–2007 De La Pedrosa et al., 2009
Switzerland 70.6 23.5 0 5.9 2003–2004 Farrell et al., 2008
Turkey 44.4 11.1 44.4 2008–2009 Sirekbasan et al., 2015
United Kingdom 20.8 70.8 4.2 4.2 2003–2004 Farrell et al., 2008
NORTH AMERICA
Canada 27.0 50.0 95 5 19.0 3.6 1997–2002 Wierzbowski et al., 2005b
2008 Wierzbowski et al., 2014
Mexico 17.2 72.4 10.3 0 2003–2004 Farrell et al., 2008
(Continued)
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TABLE 1 | Continued
Continent
Country
Macrolide resistance genotype distribution % Years References
erm(B) mef(A/E) mef(E) mef(A) erm(B) + mef(E) Negativea
USA 19.5 51.3 28.7 0.5 2007 Hawkins et al., 2015
Alaska 15.0 58.8 20.0 6.3 2006–2010 Rudolph et al., 2013
Arizona 5 25 2.5 67.5 2007–2008 Bowers et al., 2012
SOUTH AMERICA
Argentina 19.2 76.9 3.8 2009–2010 Reijtman et al., 2013
Brazil 36.0 44.0 20.0 2007–2012 Caierão et al., 2014
Colombia 56.9 40.2 30.7 0.9 7.1 4.4 1994–2008 Ramos et al., 2014
53.7 0 6.1 2005–2008 Hidalgo et al., 2011
Peru 53.3 33.3 0 13.3 2003–2004 Farrell et al., 2008
Venezuela 83.3 12.5 0.0 4.2 2007 Quintero et al., 2011
aPCR negative for erm(B), mef(A/E), mef(A), and mef(E). Some authors have determined these to be ribosomal mutations.
bStrains contain both erm(B) and mef(A).
cStrains contain mef(I).
model for macrolide eﬄux in S. pneumoniae may be macrolide
displacement from ribosomes by mel, which transfers macrolide
molecules tomef (E) for eﬄux.
S. pneumoniae with mef (E)/mel have been shown to have
an M phenotype, which is resistant to 14- and 15-membered
macrolides but susceptible to lincosamides and streptogramin
B (Tait-Kamradt et al., 1997). While mef (E)/mel-containing
strains display low level resistance (MICs 1–8µg/ml) to
erythromycin, macrolide induction increases expression of
mef (E)/mel and results in increased levels of macrolide resistance
(Wierzbowski et al., 2005a). Induction of mef (E)/mel by
macrolides increases MICs to ≥16µg/ml (Ambrose et al., 2005;
Chancey et al., 2011). The presence of the two-component
eﬄux pump encoded by mef (E)/mel also increases resistance
to the human antimicrobial peptide LL-37 (Zähner et al.,
2010). LL-37 also induces expression of the eﬄux pump
(Zähner et al., 2010). These data may suggest the eﬄux pump
is induced during nasopharyngeal colonization and primes
the mef (E)/mel-containing pneumococci to resist macrolide
antibiotics.
Ribosomal Mutations
Point mutations in 23S rRNA at or near the macrolide binding
residue A2058 (E. coli ribosome) have resulted in high-level
macrolide resistance (Vester and Douthwaite, 2001; Franceschi
et al., 2004). Mutations of ribosomal proteins L4 and L22 confer
macrolide resistance in pathogenic and nonpathogenic bacteria
including pneumococci. L4 and L22 are ribosomal proteins with
domains on the surface of the ribosome as well as tentacles that
extend into the exit tunnel in proximity to the macrolide-binding
site (Schuwirth et al., 2005). In E. coli, a Lys-63-Glu change in
the L4 protein (rplD) as well as a triple amino acid deletion of
Met-82, Lys-83, and Glu-84 from L22 (rplV) confer resistance
to macrolides (Wittmann et al., 1973; Chittum and Champney,
1994). A variety of additional L4 and L22 mutations have also
been found to confer macrolide resistance (Zaman et al., 2007;
Diner and Hayes, 2009). While the overall incidence is rare in
S. pneumoniae, L4 and L22 mutations have been shown to result
in macrolide resistance (Franceschi et al., 2004).
Dual Macrolide Resistance Genotype
S. pneumoniae containing both erm(B) and mef (E)/mel were
first reported in the late-1990s (Corso et al., 1998; Nishijima
et al., 1999) and are now found worldwide (Farrell et al., 2008).
The dual macrolide resistance genotype occurred in 12% of
global isolates collected from 2003 to 2004, which is twice the
frequency reported from 1999 to 2000 (Farrell et al., 2008).
In 2004, 18.4% of S. pneumoniae isolates from the US were
found to have the dual erm(B) andmef (E)/mel genotype (Jenkins
et al., 2008); in a recent study, up to 52% of macrolide-resistant
isolates from Arizona were found to contain both macrolide
resistance genes (Bowers et al., 2012). Tn2010 has been identified
as the major composite mobile element that contains erm(B)
and mef (E)/mel (Mega) (Del Grosso et al., 2006). Following
introduction of the 7-valent pneumococcal conjugate vaccine
(PCV-7) the “replacement” serotype 19A (ST320) with Tn2010
emerged (Del Grosso et al., 2007). ST320 is a multidrug resistant
strain that appears to represent a “capsule switch” from serotype
19F and is responsible for a global pandemic in the wake of PCV-
7 introduction (Moore et al., 2008; Li et al., 2011). The high-level
and broader resistance conferred by erm(B) would predict that






The mef (E)/mel-containing genetic element Mega is
found in at least six distinct chromosomal sites within
the pneumococcal genome (Chancey et al., 2015a), while
mef (A) is found on Tn1207.1 (Xu et al., 2010). Mega
insertion sites are distributed around the chromosome: (I)
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a phosphomethylpyrimidine kinase (TIGR4 SP_1598), (II) a
DNA-3-methyladenine glycosylase (SP_0180), (III) a capsule
biosynthesis gene (SP_0103), (IV) the RNA methyltransferase
rumA (SP_1029) (Gay and Stephens, 2001), (V) orf6 of
Tn916-like elements (Del Grosso et al., 2006), and (VI)
a novel insertion into a S. suis homolog element found
in S. pneumoniae (Chancey et al., 2015a). Due to genetic
variations at insertion site IV, this class is subdivided: (IVa)
Mega and ISSmi element insertion along with deletion of
the 30.7 kb pneumococcal pathogenicity island-1 (PPI-1),
and (IVb) simple insertion of Mega into rumA with PPI-1
intact, and (IVc) same organization as IVa with a S. equi
subspecies zooepidemicus-related integrative and conjugative
element (42 kb) inserted upstream of Mega (Chancey et al.,
2015a).
The Mega element lacks genes required for transposition
(Gay and Stephens, 2001). Analysis of the Mega insertion
sites revealed a putative target sequence of 5′-TTTCCNCAA-
3′ about six base pairs upstream of the insertion and Tn916-
like coupling sequences (Chancey et al., 2015a). The genes
required for Mega transposition may be present on other
conjugative elements of the pneumococcal genome and in non-
S. pneumoniae commensal organisms (Gay and Stephens, 2001;
Chancey et al., 2015a). While Mega is infrequently transferred
through transposition, once stabilized in the genome Mega is
widely disseminated through horizontal DNA exchange and
homologous recombination.
Tn916 is the prototype conjugative transposon that contains
the tetracycline resistance gene tet(M), and is found in many
Gram-positive bacteria. Tn916 may incorporate additional
antibiotic resistance determinants which comprise larger Tn916-
like composite elements (Roberts and Mullany, 2011). The
history and molecular mechanisms of the Tn916 family are
beyond the scope of this review, but have been explored
previously (Roberts and Mullany, 2009). The most common
Tn916-like elements in S. pneumoniae containing erythromycin
resistance cassettes include Tn2009, Tn6002, and Tn2010
(Chancey et al., 2015a). Tn2009 is a Tn916-like element
with Mega inserted into orf 6 of Tn916 to provide macrolide
resistance, the M phenotype (Del Grosso et al., 2004). Tn6002
is also a Tn916-like element with macrolide resistance, with
a MLSB phenotype due to the incorporation of an erm(B)-
containing element into orf20 of Tn916 (Brenciani et al.,
2007). The erm(B) gene may also be incorporated into
Tn916. Tn917, an erm(B)-containing transposon insertion
into orf9 of Tn916 creates Tn3872 (Brenciani et al., 2007).
S. pneumoniae with the dual macrolide resistance genotype
most often contain Tn2010 or rarely the newly described
element Tn2017 (Del Grosso et al., 2009). Tn2010 is a Tn916-
like element with Mega in orf6 and the erm(B) element
in orf20 of Tn916 (Del Grosso et al., 2007). Tn2010 likely
arose through the homologous recombination of Tn2009 with
Tn6002 (Chancey et al., 2015a). A similar recombination
event likely occurred with Tn2009 and Tn3872 to create
Tn2017, which is a Tn916-like element with a Mega insertion
in orf6 and Tn917 in orf9 of Tn916 (Del Grosso et al.,
2009).
Interspecies Exchange of Macrolide
Resistance
During the growth cycle, pneumococci develop a natural state
of competence and can acquire DNA from the environment.
A mechanism of DNA repair allows for integration of new
DNA through homologous recombination (Straume et al., 2015).
The human nasopharynx is the primary ecological niche for
the pneumococcus during asymptomatic carriage (Simell et al.,
2012), where S. pneumoniae has the opportunity to acquire DNA
from other pneumococci and from commensal bacteria of the
upper respiratory tract that may act as a reservoir for antibiotic
resistance.
Other bacteria that reside in the human upper respiratory
tract carry the macrolide resistance genes. Tn6002 is the
most common erm(B)-containing mobile genetic element of S.
pyogenes (Brenciani et al., 2007). A recent study found Mega,
Tn2009, Tn6002, and Tn2010 in commensal viridans group
streptococci isolated from the human oropharynx (Brenciani
et al., 2014). In this study, S. mitis was the most commonly
isolated streptococcal species with the macrolide resistance
elements. Other Gram-positive bacteria have been shown to
carry erm(B) and/or mef (E) (Luna et al., 1999; Seppälä et al.,
2003; Santoro et al., 2014). The Tn2009 element has been
found in commensal, Gram-negative Acinetobacter junii, and
there is evidence of this Mega-containing transposon in other
Gram-negative species including E. coli, Enterobacter cloacae,
Klebsiella sp., Proteus sp., and Pseudomonas sp. (Ojo et al., 2006).
Interspecies dissemination of mobile genetic elements containing
antibiotic resistance cassettes appears common.
Asymptomatic pneumococcal carriage occurs in children and
adults with rates in children ranging from <15% to >90% in
developing countries (Shak et al., 2013). Carriage varies based
on factors including geography and socioeconomic class (O’Brien
and Nohynek, 2003; Simell et al., 2012). During nasopharyngeal
carriage, S. pneumoniae forms biofilms that enhance natural
transformation (Chao et al., 2014) and genetic exchange during
co-colonization by two pneumococcal strains is efficient with
transformation efficiencies up to 10−2 (Marks et al., 2012).
This environment may have allowed for the dissemination of
macrolide resistance determinants including the assembly and
selection of the dual macrolide resistance elements, e.g., Tn2017
and the more common Tn2010 (discussed above).
IMPACT OF PNEUMOCOCCAL
CONJUGATE VACCINES ON MACROLIDE
RESISTANCE
Between 1994 and 1999, macrolide-resistant invasive
pneumococcal disease (MR-IPD) rapidly emerged in the US
largely due infections caused by isolates containing mef (E)/mel
(Gay et al., 2000; Stephens et al., 2005). Introduction of PCV-7 in
2000 significantly reduced the incidence of MR-IPD in the US as
the highest rates of macrolide resistance were present in PCV-7
vaccine serotypes (Stephens et al., 2005; Rudolph et al., 2013;
Hawkins et al., 2015). Similar vaccine specific reductions were
observed worldwide, which was observed in Germany through
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the reduction of mef (A)-containing serotype 14 (ST9) isolates
(Bley et al., 2011; Imöhl et al., 2015). The incidence of MR-IPD
from 2002 through 2009 stabilized while macrolide-resistant
PCV-7 serotypes continued to decline; this decline was offset
by the rapid emergence of macrolide-resistant serotypes not
covered by PCV-7, specifically serotype 19A, ST320 (formerly
CC271; Del Grosso et al., 2007; Bowers et al., 2012; Chancey
et al., 2015a).
The incidence of MR-IPD caused by serotype 19A isolates
with the dual macrolide resistance phenotype (both erm(B) and
mef (E)/mel) rapidly increased from 2003 through 2010 in the
US and worldwide (Li et al., 2011; Quintero et al., 2011; Bowers
et al., 2012; Sharma et al., 2013; Pan et al., 2015; Lyu et al.,
2016). Selective pressure by PCV-7 and the continued high-level
use of macrolides provided an opportunity for this 19A clone to
expand worldwide. The introduction of PCV-13 in the later-2010,
which contains serotype 19A, was successful in reducing carriage
and IPD caused by vaccine serotypes including macrolide-
resistant serotype 19A isolates (Desai et al., 2015; Imöhl et al.,
2015). Overall, pneumococcal conjugate vaccination has yielded
sustained reductions in pneumococcal disease (Pilishvili et al.,
2010). Despite challenges with serotype replacement, PCVs are
an effective intervention in reducing the incidence of disease
caused bymacrolide-resistant pneumococcal serotypes contained
in the vaccine. Continued expansion of pediatric pneumococcal
vaccination into developing countries is predicted to greatly
reduce the global burden of pneumococcal disease and antibiotic
resistant pneumococci (Rodgers and Klugman, 2011).
CONCLUSIONS
Macrolide resistance rapidly emerged in S. pneumoniae
in the early-1990s. The introduction and widespread use
of semisynthetic macrolides including azithromycin and
clarithromycin were important drivers of macrolide resistance
in pneumococci. Macrolide resistance in S. pneumoniae
is predominantly due to ribosomal methylation by the
gene product encoded by erm(B) and macrolide eﬄux by
a two-component eﬄux pump encoded by mef (E)/mel on
the transformable genetic element Mega. Both of these
macrolide resistance determinants are associated with larger
composite elements (i.e., Tn6002 and Tn2009) and can be
found on the same element. PCVs are effective in reducing
macrolide resistance caused by vaccine serotypes and thus
have been effective in the reduction of MR-IPD caused by
vaccine strains. But “serotype replacement” has been an
issue (e.g., 19A) and emergence of macrolide resistance
in new serotypes is a concern. Continued research is
needed to better understand the mechanism of macrolide
eﬄux by Mef(E)/Mel, the emergence of genetic elements
containing both erm(B) and mef (E)/mel, and to continue
surveillance to monitor new changes in macrolide resistance in
pneumococci.
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